Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents

International Journal of Cancer

Volumn 131, Issue 1, 2012, Pages 59-69

  Uboldi, S ^a   Bernasconi, S ^a   Romano, M ^a   Marchini, S ^a   Fuso Nerini, I ^a   Damia, G ^a   Ganzinelli, M ^a   Marangon, E ^a   Sala, F ^a   Clivio, L ^a   Chiorino, G ^b   Giandomenico, S Di ^a   Rocchi, M ^c   Capozzi, O ^c   Margison, G P ^d   Watson, A J ^d   Caccuri, A M ^e   Pastore, A ^f   Fossati, A ^g   Mantovani, R ^g   Grosso, F ^h,i   Tercero, J C ^j   Erba, E ^a   D'Incalci, M ^a   more..

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Fondo Edo Tempia   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ Medical Oncology   (Italy)

^j PHARMAMAR S A   (Spain)

more..

Author keywords

FUS CHOP; myxoid liposarcoma; resistance; trabectedin

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; DOXORUBICIN; GLUTATHIONE; MELPHALAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PENTRAXIN 3; TEMOZOLOMIDE; TRABECTEDIN;

APOPTOSIS; ARTICLE; CELL STRESS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; DRUG RESISTANCE; DRUG SENSITIVITY; EXCISION REPAIR; FN1 GENE; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE FUSION; GENE PRODUCT; GENE SEQUENCE; GENETIC TRANSCRIPTION; MODULATION; MYXOSARCOMA; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PTX3 GENE; SARCOMA CELL; SIGNAL TRANSDUCTION; ULTRAVIOLET RADIATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; C-REACTIVE PROTEIN; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE, TUMOR; DACARBAZINE; DIOXOLES; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; FIBRONECTINS; HUMANS; LIPOSARCOMA, MYXOID; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS, GENETIC; RNA-BINDING PROTEIN FUS; SERUM AMYLOID P-COMPONENT; SIGNAL TRANSDUCTION; TETRAHYDROISOQUINOLINES; TRANSCRIPTION FACTOR CHOP; TUMOR SUPPRESSOR PROTEINS; ULTRAVIOLET RAYS;

EID: 84860220336     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26340     Document Type: Article

References (48)

1. Valoti G, Nicoletti MI, Pellegrino A, Jimeno J, Hendriks H, D'Incalci M, Faircloth G, Giavazzi R,. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 1998; 4: 1977-83.
2. Izbicka E, Lawrence R, Raymond E, Eckhardt G, Faircloth G, Jimeno J, Clark G, Von Hoff DD,. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC- 648766) against human tumors explanted from patients. Ann Oncol 1998; 9: 981-7.
3. Hendriks HR, Fiebig HH, Giavazzi R, Langdon SP, Jimeno JM, Faircloth GT,. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 1999; 10: 1233-40.
4. Meco D, Colombo T, Ubezio P, Zucchetti M, Zaffaroni M, Riccardi A, Faircloth G, Jose J, D'Incalci M, Riccardi R,. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003; 52: 131-8.
5. D'Incalci M, Colombo T, Ubezio P, Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R, Sessa C, Cavallini E, Jimeno J, et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 2003; 39: 1920-6.
6. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E, Misset JL,. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22: 890-9.
7. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European organisation for the research and treatment of cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23: 576-84.
8. Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005; 23: 5484-92.
9. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8: 595-602.
10. Grosso F, Sanfilippo R, Virdis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Pilotti S, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009; 20: 1439-44.
11. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-96.
12. Casali PG, Sanfilippo R, D'Incalci M,. Trabectedin therapy for sarcomas. Curr Opin Oncol 2010; 22: 342-6.
13. Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, Zanaboni F, Gianni L, Marsoni S, Jimeno J, D'Incalci M, Dall'o E, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 23: 1867-74.
14. Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME,. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007; 97: 1618-24.
15. 2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009; 20: 1794-802.
16. Carter NJ, Keam SJ,. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs 2010; 70: 355-76.
17. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28: 3107-14.
18. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW,. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996; 35: 13303-9.
19. Moore BM, II, Seaman FC, Hurley LH,. NMR-based model of an ecteinascidin 743-DNA adduct. J Am Chem Soc 1997; 119: 5475-6.
20. Hurley LH, Zewail-Foote M,. The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability. Adv Exp Med Biol 2001; 500: 289-99.
21. Gago F, Hurley LH,. Devising a structural basis for the potent cytotoxic effects of ecteinascidin 743. In:, Demeunynck M, Bailly C, Wilson WD, editors. Small molecule DNA and RNA binders: from synthesis to nuclear acid complexed. Weinheim, Germany: Wiley-VCH; 2002. 643-75.
22. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R,. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 2000; 97: 6780-4.
23. Jin S, Gorfajn B, Faircloth G, Scotto KW,. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 2000; 97: 6775-9.
24. Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D'Incalci M,. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001; 92: 583-8.
25. Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D'Incalci M,. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001; 37: 97-105.
26. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y,. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001; 7: 961-6.
27. Zewail-Foote M, Li VS, Kohn H, Bearss D, Guzman M, Hurley LH,. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem Biol 2001; 8: 1033-49.
28. Stevens EV, Nishizuka S, Antony S, Reimers M, Varma S, Young L, Munson PJ, Weinstein JN, Kohn EC, Pommier Y,. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther 2008; 7: 10-8.
29. Soares DG, Poletto NP, Bonatto D, Salvador M, Schwartsmann G, Henriques JA,. Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways. Biochem Pharmacol 2005; 70: 59-69.
30. Tavecchio M, Simone M, Erba E, Chiolo I, Liberi G, Foiani M, D'Incalci M, Damia G,. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 2008; 44: 609-18.
31. Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, Casali P, D'Incalci M, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009; 8: 449-57.
32. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010; 70: 2235-44.
33. Aman P, Ron D, Mandahl N, Fioretos T, Heim S, Arheden K, Willen H, Rydholm A, Mitelman F,. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer 1992; 5: 278-85.
34. Montefalcone G, Tempesta S, Rocchi M, Archidiacono N,. Centromere repositioning. Genome Res 1999; 9: 1184-8.
35. Marchini S, Mariani P, Chiorino G, Marrazzo E, Bonomi R, Fruscio R, Clivio L, Garbi A, Torri V, Cinquini M, Dell'Anna T, Apolone G, et al. Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res 2008; 14: 7850-60.
36. Antonescu CR, Tschernyavsky SJ, Decuseara R, Leung DH, Woodruff JM, Brennan MF, Bridge JA, Neff JR, Goldblum JR, Ladanyi M,. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 2001; 7: 3977-87.
37. Erba E, Bergamaschi D, Bassano L, Ronzoni S, Di Liberti G, Muradore I, Vignati S, Faircloth G, Jimeno J, D'Incalci M,. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743). Br J Cancer 2000; 82: 1732-9.
38. Rosing H, Hillebrand MJ, Jimeno JM, Gomez A, Floriano P, Faircloth G, Henrar RE, Vermorken JB, Cvitkovic E, Bult A, Beijnen JH,. Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom 1998; 33: 1134-40.
39. Pastore A, Massoud R, Motti C, Lo Russo A, Fucci G, Cortese C, Federici G,. Fully automated assay for total homocysteine, cysteine, cysteinylglycine, glutathione, cysteamine, and 2-mercaptopropionylglycine in plasma and urine. Clin Chem 1998; 44: 825-32.
40. Watson AJ, Margison GP,. O6-alkylguanine-DNA alkyltransferase assay. Methods Mol Biol 2000; 152: 49-61.
41. Caretti G, Salsi V, Vecchi C, Imbriano C, Mantovani R,. Dynamic recruitment of NF-Y and histone acetyltransferases on cell-cycle promoters. J Biol Chem 2003; 278: 30435-40.
42. Verbeek B, Southgate TD, Gilham DE, Margison GP,. O6-methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull 2008; 85: 17-33.
43. van Nifterik KA, van den Berg J, van der Meide WF, Ameziane N, Wedekind LE, Steenbergen RD, Leenstra S, Lafleur MV, Slotman BJ, Stalpers LJ, Sminia P,. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer 2010; 103: 29-35.
44. Panagopoulos I, Mertens F, Isaksson M, Mandahl N,. A novel FUS/CHOP chimera in myxoid liposarcoma. Biochem Biophys Res Commun 2000; 279: 838-45.
45. Antonescu CR, Elahi A, Healey JH, Brennan MF, Lui MY, Lewis J, Jhanwar SC, Woodruff JM, Ladanyi M,. Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements. Clin Cancer Res 2000; 6: 2788-93.
46. Orvieto E, Furlanetto A, Laurino L, Dei Tos AP,. Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia. Semin Diagn Pathol 2001; 18: 267-73.
47. Tavecchio M, Natoli C, Ubezio P, Erba E, D'Incalci M,. Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach. Cell Prolif 2007; 40: 885-904.
48. Abril N, Margison GP,. Mammalian cells expressing Escherichia coli O6-alkylguanine-DNA alkyltransferases are hypersensitive to dibromoalkanes. Chem Res Toxicol 1999; 12: 544-51.